US 9765147
Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 9765147 (Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer) held by Five Prime Therapeutics, Inc. expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 31
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545